CA2009578A1 - Antagonistes des recepteurs d'acide amine excitateur - Google Patents

Antagonistes des recepteurs d'acide amine excitateur

Info

Publication number
CA2009578A1
CA2009578A1 CA2009578A CA2009578A CA2009578A1 CA 2009578 A1 CA2009578 A1 CA 2009578A1 CA 2009578 A CA2009578 A CA 2009578A CA 2009578 A CA2009578 A CA 2009578A CA 2009578 A1 CA2009578 A1 CA 2009578A1
Authority
CA
Canada
Prior art keywords
amino acid
receptor antagonists
acid receptor
excitatory amino
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2009578A
Other languages
English (en)
Other versions
CA2009578C (fr
Inventor
Paul Leslie Ornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly And Company
Paul Leslie Ornstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, Paul Leslie Ornstein filed Critical Eli Lilly And Company
Publication of CA2009578A1 publication Critical patent/CA2009578A1/fr
Application granted granted Critical
Publication of CA2009578C publication Critical patent/CA2009578C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CA002009578A 1989-02-13 1990-02-08 Antagonistes des recepteurs d'acide amine excitateur Expired - Fee Related CA2009578C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/309,562 1989-02-13
US07/309,562 US4902695A (en) 1989-02-13 1989-02-13 Excitatory amino acid receptor antagonists

Publications (2)

Publication Number Publication Date
CA2009578A1 true CA2009578A1 (fr) 1990-08-13
CA2009578C CA2009578C (fr) 1999-07-06

Family

ID=23198722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002009578A Expired - Fee Related CA2009578C (fr) 1989-02-13 1990-02-08 Antagonistes des recepteurs d'acide amine excitateur

Country Status (21)

Country Link
US (1) US4902695A (fr)
EP (2) EP0658545B1 (fr)
JP (1) JP2840102B2 (fr)
KR (1) KR900012911A (fr)
CN (1) CN1034552C (fr)
AT (1) ATE125255T1 (fr)
AU (1) AU621454B2 (fr)
CA (1) CA2009578C (fr)
DE (2) DE69033308T2 (fr)
DK (1) DK0383504T3 (fr)
ES (2) ES2137320T3 (fr)
GR (1) GR3017479T3 (fr)
HU (1) HUT53879A (fr)
IE (1) IE66996B1 (fr)
IL (1) IL93325A0 (fr)
MX (1) MX19448A (fr)
NZ (1) NZ232450A (fr)
PH (1) PH26152A (fr)
PT (1) PT93110B (fr)
RU (1) RU2063965C1 (fr)
ZA (1) ZA90944B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997821A (en) * 1988-10-21 1991-03-05 Cordi Alexis A Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
US5177240A (en) * 1988-10-21 1993-01-05 G. D. Searle & Co. O-phosphono(alkyl)-n-sulfonyl-phenyl-alanine derivatives useful as intermediates for preparation of phosphono-hydroisoquinolines
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
GB9125485D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5753634A (en) * 1992-05-29 1998-05-19 The Procter & Gamble Company Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5470978A (en) * 1992-11-18 1995-11-28 Eli Lilly And Company Process and intermediates for the preparation of excitatory amino acid receptor antagonists
US5338851A (en) * 1993-03-31 1994-08-16 Eli Lilly And Company Synthesis of cis-decahydroisoquinoline-3-carboxylic acids
ES2087812B1 (es) * 1993-07-02 1997-03-16 Lilly Co Eli Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores.
US5491241A (en) * 1993-10-18 1996-02-13 Eli Lilly And Company Bicyclic intermediates for excitatory amino acid receptor antagonists
TW280819B (fr) * 1993-11-17 1996-07-11 Sumitomo Pharma
PL179448B1 (pl) * 1994-01-31 2000-09-29 Pfizer Neuroochronne zwiazki chromanoloweoraz kompozycje farmaceutyczne zawierajace te zwiazki PL PL PL PL PL
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
CN1151130C (zh) * 1994-08-18 2004-05-26 辉瑞大药厂 神经保护的3-(哌啶基-1)-苯并二氢吡喃-4,7-二醇和1-(4-氢化苯基)-2-(哌啶基-1)链烷醇衍生物
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
JP2000515501A (ja) * 1996-07-01 2000-11-21 イーライ・リリー・アンド・カンパニー 低血糖化および低脂血化用化合物群
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
EP1077944A1 (fr) * 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Composes de carboxamide, compositions et methodes d'inhibition de l'activite de type poly(adp-ribose) polymerase (parp)
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
WO2001091796A2 (fr) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methodes, composes et compositions permettant de traiter la goutte
US6545011B2 (en) 2000-07-13 2003-04-08 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
WO2003091243A1 (fr) * 2002-04-26 2003-11-06 Eli Lilly And Company Derives ester d'un acide decahydroisoquinoline-3 carboxylique utiles en tant qu'analgesiques
US7205315B2 (en) 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
EP3427729A1 (fr) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probénécide destiné à être utilisé dans le traitement de maladies, troubles ou états épileptiques

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2487829A2 (fr) * 1979-12-07 1982-02-05 Science Union & Cie Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2546886B2 (fr) * 1983-06-06 1986-05-16 Adir Derives d'acides isoindoledicarboxyliques, leur preparation et compositions pharmaceutiques les contenant
JPS609493A (ja) * 1983-06-30 1985-01-18 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ＭＹ３３６−ａおよびその製造法
HU189765B (en) * 1983-10-25 1986-07-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for preparing n-substituted 1-(bis (hydroxy-metiol)-methyl)-isoquinoline-derivatives
FR2557570B1 (fr) * 1984-01-04 1986-04-18 Adir Nouveaux derives de la quinoleine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
EP0275820B1 (fr) * 1986-11-21 1991-02-06 Ciba-Geigy Ag Acides phosphoniques insaturés et leurs dérivés
US4761405A (en) * 1987-03-04 1988-08-02 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
ATE87918T1 (de) * 1988-02-19 1993-04-15 Lilly Co Eli Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
GB8807922D0 (en) * 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Isoquinoline compound & process for preparation thereof
AU6368090A (en) * 1989-10-03 1991-04-11 Warner-Lambert Company Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity

Also Published As

Publication number Publication date
EP0658545B1 (fr) 1999-09-29
IE900456L (en) 1990-08-13
DE69033308T2 (de) 2000-02-24
ATE125255T1 (de) 1995-08-15
CN1034552C (zh) 1997-04-16
KR900012911A (ko) 1990-09-03
HUT53879A (en) 1990-12-28
IE66996B1 (en) 1996-02-21
DE69020918T2 (de) 1995-12-21
US4902695A (en) 1990-02-20
EP0383504A3 (fr) 1991-04-10
ES2137320T3 (es) 1999-12-16
ES2076303T3 (es) 1995-11-01
AU4936990A (en) 1990-08-16
JPH02255660A (ja) 1990-10-16
MX19448A (es) 1993-11-01
PH26152A (en) 1992-03-18
IL93325A0 (en) 1990-11-29
ZA90944B (en) 1991-10-30
PT93110A (pt) 1990-08-31
DE69033308D1 (de) 1999-11-04
PT93110B (pt) 1996-06-28
EP0383504A2 (fr) 1990-08-22
RU2063965C1 (ru) 1996-07-20
DE69020918D1 (de) 1995-08-24
NZ232450A (en) 1991-05-28
GR3017479T3 (en) 1995-12-31
AU621454B2 (en) 1992-03-12
EP0383504B1 (fr) 1995-07-19
EP0658545A1 (fr) 1995-06-21
JP2840102B2 (ja) 1998-12-24
HU900725D0 (en) 1990-04-28
CN1044816A (zh) 1990-08-22
CA2009578C (fr) 1999-07-06
DK0383504T3 (da) 1995-11-27

Similar Documents

Publication Publication Date Title
CA2009578A1 (fr) Antagonistes des recepteurs d'acide amine excitateur
MY131442A (en) Excitatory amino acid receptor antagonists
IE902288L (en) Tetrazolylmethylpiperidine carboxylic acid
MY115977A (en) Synthetic excitatory amino acids
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
EP0397697A4 (en) Quinoline derivatives as antagonists of leukotriene d 4?
AU3009089A (en) Tetrazole excitatory amino acid receptor antagonists
AU6995391A (en) Intermediates in the preparation of novel bicyclic esters and amides useful as specific 5-ht3 antagonists
AU5491490A (en) Excitatory amino acid antagonists
ZA894145B (en) Serotonin antagonists
SI0648762T1 (en) Bicyclic compounds as excitatory amino acid receptor antagonists
TW197410B (fr)
JPS6416740A (en) Manufacture of intermediate for leukotriene antagonist

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed